Trials / Suspended
SuspendedNCT00079950
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Enzon Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Pegamotecan (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegamotecan |
Timeline
- Start date
- 2003-08-01
- First posted
- 2004-03-22
- Last updated
- 2012-09-06
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00079950. Inclusion in this directory is not an endorsement.